Overview

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Status:
Unknown status

Trial end date:
2018-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety of lenalidomide and markers for disease progression in the treatment of IPSS low- or intermediate-1 risk MDS with isolated del5q.

Phase:

Phase 2

Details

Lead Sponsor:

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Collaborator:

ClinAssess GmbH

Treatments:

Lenalidomide
Thalidomide